- Home
- ATXS vs VIR Comparison
ATXS vs VIR Comparison
Compare ATXS & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- VIR
- Stock Information
- Founded
- ATXS 2008
- VIR 2016
- Country
- ATXS United States
- VIR United States
- Employees
- ATXS N/A
- VIR N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- ATXS Health Care
- VIR Health Care
- Exchange
- ATXS Nasdaq
- VIR Nasdaq
- Market Cap
- ATXS 676.1M
- VIR 773.5M
- IPO Year
- ATXS 2015
- VIR 2019
- Fundamental
- Price
- ATXS $12.50
- VIR $5.73
- Analyst Decision
- ATXS Hold
- VIR Strong Buy
- Analyst Count
- ATXS 6
- VIR 11
- Target Price
- ATXS $24.33
- VIR $25.73
- AVG Volume (30 Days)
- ATXS 936.9K
- VIR 1.3M
- Earning Date
- ATXS 11-12-2025
- VIR 11-05-2025
- Dividend Yield
- ATXS N/A
- VIR N/A
- EPS Growth
- ATXS N/A
- VIR N/A
- EPS
- ATXS N/A
- VIR N/A
- Revenue
- ATXS $706,000.00
- VIR $16,860,000.00
- Revenue This Year
- ATXS N/A
- VIR N/A
- Revenue Next Year
- ATXS N/A
- VIR $15.25
- P/E Ratio
- ATXS N/A
- VIR N/A
- Revenue Growth
- ATXS N/A
- VIR N/A
- 52 Week Low
- ATXS $3.56
- VIR $4.16
- 52 Week High
- ATXS $12.72
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- ATXS 67.29
- VIR 52.58
- Support Level
- ATXS $12.31
- VIR $5.32
- Resistance Level
- ATXS $12.62
- VIR $5.86
- Average True Range (ATR)
- ATXS 0.23
- VIR 0.32
- MACD
- ATXS -0.17
- VIR 0.00
- Stochastic Oscillator
- ATXS 72.73
- VIR 86.60
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.